Is SHPG a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

785 people get SHPG articles and Market Currents by email alert.

Get email alerts on SHPG »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Shire's New Rare Disease Deal: Interesting Science Meets Unique Financing
Alan Kotok • Mon, May 13
New Shire CEO Onrskov Hopes To Build On Predecessor's Success
Stock Traders Daily • Fri, Mar 1
If Investors Won't Buy Shire, Big Pharma Should
Stephen Simpson • Wed, Feb 20
Shire Moves to Acquire Movetis
The Burrill Report • Thu, Aug 5, 2010
Shire Seeks FDA Approval for Replagal
Zacks Investment Research • Mon, Dec 28, 2009
Shire May Have Another Winner in Purchase of Jerini
Eben Tessari • Mon, Jul 7, 2008

If Investors Won't Buy Shire, Big Pharma Should
Stephen Simpson • Wed, Feb 20

Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market
Brian Marckx • Wed, Jun 12 • 3 Comments
Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
PropThink • Tue, Jun 4
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 6 Comments
What Will It Take For Stem Cell Companies To Close The Valuation Gap?
Life Sciences Report • Wed, Apr 17 • 1 Comment
Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design
Nouvelle Asset Management • Fri, Apr 5 • 4 Comments
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
PropThink • Wed, Apr 3
Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself
Brian Nichols • Tue, Mar 19 • 2 Comments
Don't Fold On Amicus Therapeutics Just Yet
Stephen Simpson • Wed, Feb 27 • 13 Comments
After The Twists And Turns, Sanofi Still A Value
Stephen Simpson • Tue, Feb 12 • 7 Comments
After 2 Drug Approvals, Can Supernus Deliver In 2013?
C.R. Jackson • Mon, Nov 26, 2012 • 3 Comments
Keryx Is Completely Misunderstood And May Double On Data
PropThink • Wed, Nov 21, 2012 • 1 Comment
5 Big Buys By Paulson & Co
Efsinvestment • Tue, Nov 20, 2012
Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
LifeSci Advisors • Mon, Oct 1, 2012 • 4 Comments
Will Stem Cell Research Lift Pharmaceutical Stock Values?
George Kesarios • Wed, Sep 26, 2012 • 3 Comments
Dyax And ViroPharma: An Overview Of HAE Space
LifeSci Advisors • Tue, Sep 18, 2012
Sangamo Biosciences: Could It Have A Cure For HIV?
Rx Stocks • Fri, Jul 27, 2012 • 2 Comments
Spectrum Pharmaceuticals: Bears Beware, Fusilev Strength Points To Strong Second Quarter
Smith On Stocks • Sun, Jul 15, 2012 • 23 Comments
Pfizer May Sink On New Drug Woes
Stock Croc • Tue, Jul 10, 2012 • 3 Comments
Gaucher Disease: The Fight For Market Share
Peter Geschek • Sun, Jul 1, 2012 • 2 Comments
Characteristics Of High Dividend Growth Companies
Adam Bauer • Tue, Jun 26, 2012 • 38 Comments

Shire Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Shire's CEO Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Shire Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 14
Shire Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
Shire Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 1, 2012
Shire's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Shire plc's CEO Discusses 2011 Results - Earnings Call Transcript
Thu, Feb 9, 2012
Shire plc's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011 • 1 Comment
Shire plc's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Jul 28, 2011
Shire plc CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 10, 2011
Shire Plc. CEO Discusses Q3 2010 Results - Earnings Call Transcript
Fri, Oct 29, 2010
Shire Plc. Q2 2010 Earnings Call Transcript
Thu, Aug 5, 2010
Shire plc Q4 2009 Earnings Call Transcript
Fri, Feb 19, 2010
Shire plc Q3 2009 Earnings Call Transcript
Sun, Nov 1, 2009
Shire plc Q2 2009 Earnings Call Transcript
Wed, Aug 5, 2009
Shire Plc. Q4 2008 Earnings Call Transcript
Mon, Mar 2, 2009
Shire plc Q3 2007 Earnings Call Transcript
Sun, Nov 4, 2007

Drug companies look to profit from DSM-5

at MarketWatch.com (Jun 5, 2013)
Europe Markets: European stocks edge up as ECB cuts rates

at MarketWatch.com (May 2, 2013)

SHPG vs. ETF Alternatives

Company Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United Kingdom

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 20, 11:04 AM Sangamo BioSciences (SGMO -4.5%) takes a bit of a hit this morning, despite the presentation of new data demonstrating the successful application of its In Vivo Protein Replacement Platform in a mouse model. The company, in partnership with Shire (SHPG +1.8%), is developing ZFP Therapeutics for both hemophilia A and B using this approach. The data was presented late last week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City. 3 Comments [Healthcare, On the Move]
Friday, May 10, 1:14 PM Shire (SHPG -0.2%) lags the overall market after JP Morgan/Cazenove cut the shares to Neutral, citing a lack of catalysts. The firm says its pipeline is now a 2014 story, as its Phase III studies of Vyvanse for depression, as well as versus Concerta for ADHD, aren't likely to have any impact over the near term. Comment! [Healthcare, Global & FX]
Thursday, May 2, 9:08 AM Shire plc (SHPG): Q1 Earning per ADS of $1.63. Revenue of $1.16B misses by $0.05B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:13 PM Actavis (ACT +1%) reaches a settlement with Shire (SHPG +1.6%) regarding an outstanding patent litigation related to ACT's generic version of Intuniv, a treatment for ADHD. Under the terms of the settlement, ACT can launch its generic version of Intuniv on December 1, 2014, or earlier under certain circumstances. SHPG will receive a 25% royalty on gross profits from sales during the period of exclusivity. Comment! [Healthcare, On the Move]
Monday, March 25, 8:26 AM Shire (SHPG) will acquire California-based, privately held biopharmaceutical company SARcode Bioscience for an upfront payment of $160M plus additional undisclosed payments as certain milestones are met. Shire says the acquisition will strengthen its portfolio by adding a phase 3 compound called LIFITEGRAST indicated for the treatment of dry eye disease. Comment! [Healthcare, M&A]
Tuesday, March 12, 8:39 AM Shire (SHPG +0.3% in London) has acquired closely held Swedish company Premacure, which is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare eye disorder that primarily affects premature babies and is one of the most common causes of blindness in childhood. The treatment is in Phase II trials. Shire made an upfront payment and will pay royalties. (PR) Comment! [Healthcare, M&A]
Thursday, February 14, 3:10 PM Teva Pharmaceutical (TEVA +0.3%) says the FDA has approved its Abbreviated New Drug Application for the generic version of Shire's (SHPG) Adderall XR capsules for the treatment of ADD. Adderall XR had annual sales, including brand and generic sales, of approximately $2B in the U.S. last year. 5 Comments [Healthcare]
Thursday, February 14, 8:04 AM More on Shire (SHPG) Q4: adjusted operating income flat at $368M as sales gained 5%, although results were hurt by generic competition for Adderall XR (ADHD). Expects 2013 earnings per ADS of $6.72, in line with consensus, but forecasts royalties and other revenues to fall 30-40%. Shares -3.7%. (PR) Comment! [Earnings, Healthcare]
Thursday, February 14, 7:21 AM Shire (SHPG): Q4 EPS of $1.58. Revenue of $1.2B in-line. Shares -4% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Thursday, February 14, 12:05 AM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
Wednesday, February 13, 5:30 PM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
Tuesday, February 12, 3:33 PM AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall Street analysts, saying the drugmaker needs a "transformational deal" to return it to profit growth. A deal for Shire (SHPG +0.2%) or Forest Labs (FRX +0.7%) would rival its's $15B acquisition of MedImmune in 2007. SHPG could help fill the gap with patent-protected medicines for rare diseases and leading ADD therapies, says Kepler Capital Markets, while FRX's lung treatment would bolster the company's respiratory business. Comment! [Healthcare, M&A]
Wednesday, February 6, 5:14 PM More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were generated from the Company's collaboration agreements with Shire (SHPG), Dow AgroSciences (DAS) and Sigma-Aldrich Corporation (SIAL), plus additional research grants. The company guides FY2013 revenue slightly to the lower side of estimates, now expecting to earn between $20M -24M, versus the consensus of $23.09M. Shares -1% AH. Comment! [Healthcare, Earnings, On the Move]
Thursday, January 17, 7:47 AM Shire (SHPG) is +0.4% in London although it was higher earlier in the day on chatter that it might be interesting AstraZeneca (AZN +1.1%). A major acquisition of over $20B, says Credit Suisse, could be a solution to AstraZeneca's expected revenue decline. How lovely then that Shire's market cap is $18.71B. Comment! [Healthcare]
Wednesday, January 9, 9:00 AM Shire (SHPG +1.9% in London ) expects "to deliver double-digit" earnings growth in 2012, CEO Angus Russell told the JPM Healthcare conference yesterday, with the company "increasingly confident of meeting current consensus earnings expectations for 2013." Analysts predict earnings per ADS of $6.69. (Presentation) Comment! [Earnings, Healthcare]
Tuesday, January 8, 7:48 AM Shire PLC (SHPG) will acquire privately-held Lotus Tissue Repair, developer of a treatment for an orphan disease dystrophic epidermolysis bullosa. Terms were not disclosed. (PR) Comment! [Healthcare, M&A]

Ryan Mallory
Fuinhaz Setups for April 22 2013 | $BBRY $GOLD $HLIT $NSPH $PWER $SHPG $YHOO $ZNGA | SharePlanner http://bit.ly/13qxKHm
Apr 22, 9:52 AM
Reply (28)

• !Report Abuse
View all 28 replies
DumpsterDiver: Do you believe that note about PWER was NOT embarrassingly uninformed? If so, why?
May 2, 2:28 AM
• !Report Abuse
Ryan Mallory: No I don't, and what is more embarrassing is your obsession with a comment made 10 days ago.
May 2, 8:43 AM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 16 2013 | $AMGN $BBRY $FSC $GOLD $SHPG $SONS $SSRI $SVA $ZNGA | http://bit.ly/12iTo1d
Apr 16, 8:56 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/LKa5tc Premarket loser $MNTA, $GEOY, $SHPG, $ARNA, $PTNR, $DNDN, $MU, $XIV, $SVXY
6/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
Closed 5-day positions on $SHPG $RHT longs, $DUK $FLO shorts for avg mkt neutral profit of 2.5%! http://bit.ly/L4RxoJ
6/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
7 High Profitable Healthcare Dividend Stocks With Fantastic Yields + http://bit.ly/zwsRCy + $PDLI $AZN $PMD $GSK $BMY $NVO $SHPG
3/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Liquidity Services (LQDT), Sally Beauty (SBH), Buffalo Wild Wings (BWLD), Shire (SHPG), & Alexion (ALXN) rose Friday on unusual volume.
2/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Shire (SHPG), Apple (AAPL), Liquidity Services (LQDT), Alexion Pharma (ALXN), & National Oilwell Varco (NOV) rising today on unusual volume
2/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: ALXN reported great earnings!!
2/10/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Panera Bread (PNRA), Buffalo Wild Wings (BWLD), Transdigm Group (TDG), Tractor Supply (TSCO), & Shire (SHPG) rose Tuesday on unusual volume
2/8/12
Reply (1)

• !Report Abuse
View all 1 replies
AlphaVolume: you forgot PZZI.
2/8/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
13 Stocks Gaining Momentum http://bit.ly/wDrg3n AEO AMED COST CVH IXP MA MGAM ONTY SHPG SONC PCP TW XOMA
2/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Questcor Pharma (QCOR), Acorda Therapeutics (ACOR), CVR Partners (UAN), Shire (SHPG), & Ralph Lauren (RL) are rising on unusual volume.
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: That is a lot of drugmakers.
1/9/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Ryan Mallory
Fuinhaz Setups for April 22 2013 | $BBRY $GOLD $HLIT $NSPH $PWER $SHPG $YHOO $ZNGA | SharePlanner http://bit.ly/13qxKHm
Apr 22, 9:52 AM
Reply (28)

• !Report Abuse
View all 28 replies
DumpsterDiver: Do you believe that note about PWER was NOT embarrassingly uninformed? If so, why?
May 2, 2:28 AM
• !Report Abuse
Ryan Mallory: No I don't, and what is more embarrassing is your obsession with a comment made 10 days ago.
May 2, 8:43 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Shire (SHPG), Apple (AAPL), Liquidity Services (LQDT), Alexion Pharma (ALXN), & National Oilwell Varco (NOV) rising today on unusual volume
2/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: ALXN reported great earnings!!
2/10/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Panera Bread (PNRA), Buffalo Wild Wings (BWLD), Transdigm Group (TDG), Tractor Supply (TSCO), & Shire (SHPG) rose Tuesday on unusual volume
2/8/12
Reply (1)

• !Report Abuse
View all 1 replies
AlphaVolume: you forgot PZZI.
2/8/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Questcor Pharma (QCOR), Acorda Therapeutics (ACOR), CVR Partners (UAN), Shire (SHPG), & Ralph Lauren (RL) are rising on unusual volume.
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: That is a lot of drugmakers.
1/9/12
• !Report Abuse
Add a reply...

140 characters

SHPG Shire PLC

SHPG

Shire PLC